Clinical trials: Pulmonary Consolidation
Non-Small Cell Lung Carcinoma
Trial of RNActive®-Derived Cancer Vaccine and Local Radiation in in Stage IV Non Small Cell Lung Cancer (NSCLC)
The purpose of this study is to determine whether the new RNActive derived lung cancer vaccine CV9202 in combination with local radiation therapy is safe, tolerable and immunogenic for the consolidation and maintenance treatment…
- Trial name
- NCT01915524
- Testing
- CV9202, local radiation
- Where
- 13 sites in Austria, Germany and 1 more
- Volunteers
- 26 people
- Sponsor
- CureVac
Carcinoma, Non-Small-Cell Lung
A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients
This is a Phase III, randomised, double-blind, placebo-controlled, multicentre study assessing the efficacy and safety of durvalumab compared with placebo, as consolidation therapy in patients with locally advanced, unresectable…
- Trial name
- PACIFIC-5 (NCT03706690)
- Testing
- Durvalumab
- Where
- 87 sites in China, Hong Kong and 8 more
- Volunteers
- 407 people
- Sponsor
- AstraZeneca
Artificial Intelligence, Lung Diseases
Retrospective Study of Carebot AI CXR Performance in Preclinical Practice
The purpose of this study is to describe the design, methodology and evaluation of the preclinical test of Carebot AI CXR software, and to provide evidence that the investigated medical device meets user requirements in…
- Conditions
- Artificial Intelligence, Lung Diseases, Pneumothorax, Pleural Effusion
- Trial name
- NCT05594485
- Testing
- Carebot AI CXR
- Where
- Czechia
- Volunteers
- 127 people
- Sponsor
- Carebot s.r.o.
Non-Hodgkin's Lymphoma
Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Intermediate Grade Non-Hodgkin's Lymphoma Following First Line CHOP
The purpose of this study is to determine the safety and effectiveness of using Iodine-131 Anti-B1 Antibody for the treatment of patients with large B-cell non-Hodgkin's lymphoma (NHL) who have achieved a response following 6-8…
- Trial name
- NCT00022932
- Testing
- Iodine-131 Anti-B1 Antibody
- Where
- 3 sites in United States
- Sponsor
- Corixa Corporation
Cancer, Hematologic Malignancies
Consolidation Therapy in Patients With Hematologic Malignancies
The purpose of this study is to determine the safety and efficacy of Tumor Associated Peptide Antigen (TAPA) pulsed dendritic cell (DC) vaccines in the treatment of hematologic malignancies.
- Trial name
- NCT02709993
- Testing
- TAPA-pulsed DC vaccine
- Where
- United States
- Sponsor
- Kiromic BioPharma Inc.
Fallopian Tube Cancer, Ovarian Cancer
Monoclonal Antibody Therapy in Treating Patients With Residual Disease From Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Following Surgery and Chemotherapy
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00003634
- Testing
- oregovomab
- Where
- 46 sites in United States, Canada
- Volunteers
- 400 people
- Sponsor
- AltaRex
Acute Myeloid Leukemia
Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Maintenance Monotherapy in Patients With Newly-diagnosed FMS-like Tyrosine 3 (FLT3) Kinase Receptor-mutated Acute Myeloid Leukemia.
The purpose of this study was to gather and evaluate additional safety and efficacy data on the combination of midostaurin and standard of care for adult patients with newly diagnosed Fms-like tyrosine kinase receptor (FLT3)…
- Trial name
- NCT03379727
- Testing
- Midostaurin, Cytarabine, anthracycline ((daunorubicin or idarubicin): Induction Phase only
- Where
- 86 sites in Bulgaria, Croatia and 13 more
- Volunteers
- 301 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Myeloma
A Study of Bortezomib as Consolidation Therapy in Patients With Multiple Myeloma
The purpose of this study is determination of the event-free survival with and without Bortezomib consolidation therapy from the day of the first chemotherapeutic, myeloma-specific therapy measure, up to the occurrence of…
- Trial name
- NCT00416273
- Testing
- Bortezomib, No intervention
- Where
- 38 sites in Germany
- Volunteers
- 217 people
- Sponsor
- Janssen-Cilag G.m.b.H
Acute Myeloid Leukemia
SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission
This is a non-randomized, open-label, multicenter, dose escalation study designed to determine the maximum tolerated dose (MTD) of SL-401 in adult patients with acute myeloid leukemia, and to evaluate the safety profile of SL-401…
- Trial name
- NCT02270463
- Testing
- Tagraxofusp-erzs
- Where
- 7 sites in United States
- Volunteers
- 16 people
- Sponsor
- Stemline Therapeutics, Inc.
Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) / Internal Tandem Duplication (ITD) Mutation
A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission
The purpose of this study was to compare relapse-free survival (RFS) between participants with FMS-like tyrosine kinase 3 (FLT3) / internal tandem duplication (ITD) acute myeloid leukemia (AML) in first complete remission (CR1)…
- Trial name
- NCT02927262
- Testing
- Gilteritinib
- Where
- 73 sites in United States, Brazil and 19 more
- Volunteers
- 98 people
- Sponsor
- Astellas Pharma Global Development, Inc.
B-Cell Acute Lymphoblastic Leukemia
Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients
This is a single arm, open-label, multi-center, phase II study to determine the efficacy and safety of tisagenlecleucel in de novo HR pediatric and young adult B-ALL patients who received first-line treatment and are EOC MRD…
- Trial name
- CASSIOPEIA (NCT03876769)
- Testing
- CTL019
- Where
- 43 sites in United States, Belgium and 9 more
- Volunteers
- 121 people
- Sponsor
- Novartis Pharmaceuticals
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. IM-862 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood…
- Trial name
- NCT00017303
- Testing
- carboplatin, oglufanide disodium, paclitaxel
- Where
- 19 sites in United States
- Sponsor
- Cytran
Newly Diagnosed FLT3 Mutated AML
Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML
A phase III randomized multi-center study designed to compare the efficacy of crenolanib with that of midostaurin when administered following induction chemotherapy, consolidation chemotherapy and bone marrow transplantation in…
- Trial name
- NCT03258931
- Testing
- Crenolanib, Midostaurin, Cytarabine
- Where
- 31 sites in United States
- Volunteers
- 214 people
- Sponsor
- Arog Pharmaceuticals, Inc.
Lymphoma, Non-Hodgkin
Iodine-131 Anti-B1 Antibody Consolidation for Patients With Non-Hodgkin's Lymphoma Following First-line CHOP
This is a multicenter study for the long-term follow-up of surviving patients who are expected to complete or who have completed at least two years of follow-up after treatment with Iodine I 131 Tositumomab (BEXXAR) on studies…
- Trial name
- NCT01868035
- Testing
- tositumomab and iodine I-131 tositumomab
- Volunteers
- 15 people
- Sponsor
- GlaxoSmithKline
HIV Infections, Histoplasmosis
A Randomized, Open, Comparative Multicenter Study of Initial Treatment With Intravenous Itraconazole Versus Amphotericin B Followed by Consolidation Treatment With Itraconazole Capsules in Patients With Blastomycosis or Histoplasmosis
To assess the safety of intravenous itraconazole compared to amphotericin B in HIV positive or negative persons with blastomycosis or histoplasmosis.
- Conditions
- HIV Infections, Histoplasmosis, Blastomycosis
- Trial name
- NCT00002159
- Testing
- Itraconazole, Amphotericin B
- Where
- 9 sites in United States
- Volunteers
- 60 people
- Sponsor
- Janssen, LP
Limited-stage Small-cell Lung Cancer
A Study of HS-20093 vs Active Surveillance in Limited-Stage Small Cell Lung Cancer
This study will evaluate the efficacy, safety and tolerability of HS-20093 compared with active surveillance as consolidation therapy after chemoradiotherapy in participants with limited-stage small cell lung cancer.
- Trial name
- NCT06526624
- Testing
- HS-20093
- Volunteers
- 406 people
- Sponsor
- Hansoh BioMedical R&D Company
Leukaemia, Myelocytic, Acute
Evaluation of a New Anti-cancer Immunotherapy After Chemotherapy in Adult Patients With Acute Myeloid Leukemia (AML)
This study is being done to evaluate the safety of a WT1 Antigen-Specific Cancer Immunotherapeutic (WT1 ASCI) as post-consolidation therapy in adult patients with WT1-positive Acute Myeloid Leukemia in first complete remission.
- Trial name
- NCT00725283
- Testing
- GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI)
- Where
- 10 sites in United States, France
- Volunteers
- 34 people
- Sponsor
- GlaxoSmithKline
Myeloma Multiple
Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy
To assess Minimal Residual Disease (MRD)-negative Complete Response (sCR) rate after consolidation treatment with Descartes-08 in patients with high-risk myeloma who have residual disease following induction therapy.
- Trial name
- NCT04816526
- Testing
- Descartes 08
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Cartesian Therapeutics
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02
An open-label, phase I, multi-center study to determine in relapsed/refractory (r/r) acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) patients the recommended dose of CYAD-02 after a non-myeloablative…
- Trial name
- CYCLE-1 (NCT04167696)
- Testing
- CYAD-02, ENDOXAN, Fludara
- Where
- 5 sites in United States, Belgium
- Volunteers
- 27 people
- Sponsor
- Celyad Oncology SA
Newly Diagnosed Multiple Myeloma
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of standard induction regimens (IsaVRd and DRd) followed by AZD0120 versus standard induction regimens followed…
- Trial name
- DURGA-5 (NCT07764978)
- Testing
- AZD0120, Daratumumab, Dexamethasone
- Where
- 124 sites in United States, Australia and 13 more
- Volunteers
- 750 people
- Sponsor
- AstraZeneca